Sars-COV-2感染和COVID疫苗接种后单肉毒杆菌毒素和单肉毒杆菌毒素缺乏治疗效果和持续时间。

Plastic and aesthetic nursing Pub Date : 2025-07-01 Epub Date: 2025-07-09 DOI:10.1097/PSN.0000000000000610
Ali McCoy Stengel, J Cole Stengel
{"title":"Sars-COV-2感染和COVID疫苗接种后单肉毒杆菌毒素和单肉毒杆菌毒素缺乏治疗效果和持续时间。","authors":"Ali McCoy Stengel, J Cole Stengel","doi":"10.1097/PSN.0000000000000610","DOIUrl":null,"url":null,"abstract":"<p><p>This article outlines the data collection process we used to document treatment efficacy and longevity changes in 1,298 patients who received a total of 4,583 treatments with either onabotulinumtoxinA, abobotulinumtoxinA, or both during the Sars-COV-2 (COVID-19) pandemic outbreak in 2020 and the adult COVID-19 vaccination program rollout in 2021. We divided the study patients into two groups based on the year they were treated (2020 = 791; 2021 = 1,037). We did not include any new patients in the study. We found that 2.5% (n = 19) of the patients in the 2020 group experienced a lack of treatment effect and 5.2% (n = 40) experienced a decrease in treatment duration. We found that 2.1% (n = 22) of the patients in the 2021 group experienced a lack of treatment effect and 13.6% (n = 141) experienced a decrease in treatment duration. We also identified a sample population of patients who experienced a decrease in treatment duration incidents when receiving the COVID-19 vaccine after their last treatment. Our data show there is an apparent relationship between patients experiencing a lack of treatment efficacy and/or a decrease in treatment duration and having a Sars-COV-2 infection or receiving a COVID-19 vaccine.</p>","PeriodicalId":74460,"journal":{"name":"Plastic and aesthetic nursing","volume":"45 3","pages":"150-156"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Lack of Treatment Efficacy and Duration of OnabotulinumtoxinA and AbobotulinumtoxinA Post Sars-COV-2 Infection and COVID Vaccination.\",\"authors\":\"Ali McCoy Stengel, J Cole Stengel\",\"doi\":\"10.1097/PSN.0000000000000610\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This article outlines the data collection process we used to document treatment efficacy and longevity changes in 1,298 patients who received a total of 4,583 treatments with either onabotulinumtoxinA, abobotulinumtoxinA, or both during the Sars-COV-2 (COVID-19) pandemic outbreak in 2020 and the adult COVID-19 vaccination program rollout in 2021. We divided the study patients into two groups based on the year they were treated (2020 = 791; 2021 = 1,037). We did not include any new patients in the study. We found that 2.5% (n = 19) of the patients in the 2020 group experienced a lack of treatment effect and 5.2% (n = 40) experienced a decrease in treatment duration. We found that 2.1% (n = 22) of the patients in the 2021 group experienced a lack of treatment effect and 13.6% (n = 141) experienced a decrease in treatment duration. We also identified a sample population of patients who experienced a decrease in treatment duration incidents when receiving the COVID-19 vaccine after their last treatment. Our data show there is an apparent relationship between patients experiencing a lack of treatment efficacy and/or a decrease in treatment duration and having a Sars-COV-2 infection or receiving a COVID-19 vaccine.</p>\",\"PeriodicalId\":74460,\"journal\":{\"name\":\"Plastic and aesthetic nursing\",\"volume\":\"45 3\",\"pages\":\"150-156\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Plastic and aesthetic nursing\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/PSN.0000000000000610\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/9 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Plastic and aesthetic nursing","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/PSN.0000000000000610","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/9 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

本文概述了我们用于记录1298名患者的治疗疗效和寿命变化的数据收集过程,这些患者在2020年Sars-COV-2 (COVID-19)大流行爆发和2021年成人COVID-19疫苗接种计划推出期间共接受了4583次单肉毒杆菌毒素a、肉毒杆菌毒素a或两者的治疗。我们根据患者接受治疗的年份将患者分为两组(2020 = 791;2021 = 1037)。我们没有将任何新患者纳入研究。我们发现2020组中2.5% (n = 19)的患者缺乏治疗效果,5.2% (n = 40)的患者治疗时间缩短。我们发现2021组中有2.1% (n = 22)的患者缺乏治疗效果,13.6% (n = 141)的患者治疗时间缩短。我们还确定了一组患者样本,他们在最后一次治疗后接受COVID-19疫苗时,治疗持续时间事件有所减少。我们的数据显示,缺乏治疗效果和/或治疗持续时间缩短的患者与感染Sars-COV-2或接种COVID-19疫苗之间存在明显的关系。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Lack of Treatment Efficacy and Duration of OnabotulinumtoxinA and AbobotulinumtoxinA Post Sars-COV-2 Infection and COVID Vaccination.

This article outlines the data collection process we used to document treatment efficacy and longevity changes in 1,298 patients who received a total of 4,583 treatments with either onabotulinumtoxinA, abobotulinumtoxinA, or both during the Sars-COV-2 (COVID-19) pandemic outbreak in 2020 and the adult COVID-19 vaccination program rollout in 2021. We divided the study patients into two groups based on the year they were treated (2020 = 791; 2021 = 1,037). We did not include any new patients in the study. We found that 2.5% (n = 19) of the patients in the 2020 group experienced a lack of treatment effect and 5.2% (n = 40) experienced a decrease in treatment duration. We found that 2.1% (n = 22) of the patients in the 2021 group experienced a lack of treatment effect and 13.6% (n = 141) experienced a decrease in treatment duration. We also identified a sample population of patients who experienced a decrease in treatment duration incidents when receiving the COVID-19 vaccine after their last treatment. Our data show there is an apparent relationship between patients experiencing a lack of treatment efficacy and/or a decrease in treatment duration and having a Sars-COV-2 infection or receiving a COVID-19 vaccine.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.20
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信